revious studies have demonstrated that renal insufficiency is an independent risk factor for cardiovascular morbidity and for all-cause as well as cardiovascular death in both the general population and patients with cardiovascular disease. [1] [2] [3] [4] In particular, recent studies have shown that any stage of renal dysfunction (mild to severe) is an independent risk factor for short-and long-term mortality among patients with myocardial infarction (MI), even after administration of fibrinolytics. [5] [6] [7] [8] Moreover, it has been demonstrated that impaired renal function is associated with poorer clinical outcome after either percutaneous coronary intervention or coronary artery bypass graft surgery. [9] [10] [11] [12] Several recently published studies have shown that renal insufficiency is common among patients with a broad spectrum of acute coronary syndromes (ACS) at admission and is associated with higher risk of death as well as major bleeding. [13] [14] [15] [16] [17] [18] [19] However, the effect of renal insufficiency in patients with non-ST-segment elevation MI (NSTEMI) and unstable angina (UA) has been less extensively investigated.
pathologic Q waves on ECG, (c) ECG changes indicative of ischemia (ie, ST segment elevation or depression) or (d) coronary artery intervention (eg, coronary angioplasty). 21 UA was defined by the occurrence of 1 or more angina episodes at rest, within the preceding 48 h, corresponding to class III of the Braunwald classification. 22 The study was approved by the institutional Medical Research Ethics Committee and was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association. Informed consent was given by all participants.
Information was obtained about patients' sociodemographic characteristics (eg, age, sex, years of education, marital status, body mass index etc) and smoking habits. We also recorded patients' medical history, including previous hospitalization for cardiovascular disease (ie, coronary heart disease, stroke or other cardiovascular disease), presence of hypertension (medical records of blood pressure >140/90 mmHg or use of antihypertensive drugs), hypercholesterolemia (medical records of total serum cholesterol >200 mg/dl or use of lipid-lowering agents) and diabetes mellitus (use of antidiabetic medication or blood glucose >125 mg/dl) and their family medical history. We recorded the levels of troponin-I, creatinine, the MB isoenzyme of creatine kinase (CK-MB) levels, total serum cholesterol and blood pressure at the time of admission, as well as interventional procedures and in-hospital outcome.
Renal insufficiency was initially quantified by the baseline estimated creatinine clearance rate (CrCl). Based on baseline serum creatinine (Cr), the CrCl was calculated using the Cockcroft-Gault formula 23 : CrCl = [[(140 -age) × weight]/(72 × Cr)] for men; for women the result was multiplied by 0.85. Based on National Kidney Foundation recommendations, 24 patients were divided into 3 groups according to their CrCl: (1) normal renal function or mild renal insufficiency (>60 ml/min), (2) moderate renal insufficiency (60-30 ml/min), (3) severe renal insufficiency (<30 ml/min).
Statistical Analysis
Normally distributed continuous variables are expressed as mean values ± standard deviation. Skewed variables are reported as median (25 th , 75 th interquartiles) and categorical variables as absolute and relative (%) frequencies. Differences in baseline characteristics among comparison groups (normal or minimally impaired renal function, moderate and severe renal dysfunction) were evaluated using one-way analysis of variance for normally distributed continuous variables, Kruskal Wallis test for skewed variables (ie, CK-MB), whereas the chi-square test was used for the analysis of categorical variables. A test for trend across ordered groups was performed for the 3 CrCl groups. The association between renal insufficiency and in-hospital mortality rate was evaluated by univariate and multivariable logistic regression analyses, after controlling for sociodemographic, clinical and biochemical characteristics of the patients. In particular, the following were used as potential confounders: age, sex, smoking habits, body mass index, history of coronary heart disease, history of hypertension, history of diabetes mellitus, initial levels of CK-MB, as well as initial blood pressure levels, ECG changes at the admission, and the administration or not of thrombolytic therapy (only when the analysis was performed in all patients and in those suffering from STEMI). These factors were taken into account because of their prognostic importance for mortality from ACS and because they differed among the comparison groups. To evaluate whether the relationship of renal dysfunction and mortality differs according to the type of ACS, a 2-way interaction term including renal dysfunction and diagnosis was tested in the final model. In addition, the impact of renal insufficiency on mortality was assessed in patients with and without diabetes mellitus, hypertension, history of coronary heart disease, sex and age (≥65 years vs <65 years) by introducing 2-way interaction terms including these clinical variables and renal insufficiency. However, these interaction terms were not significant in the final model, so they were not included. Appropriate tests for goodness-of-fit (ie, deviance and Pearson's residuals) were used in the final models. The differences in the predictive value of the 2 models produced from those presenting with STEMI and those presenting with NSTEMI and UA, separately, were assessed using the Akaike Information Criterion (AIC), which penalizes the fit as measured by the likelihood with the number of parameters required for the fit (AIC =-2log likelihood + 2 no. parameters). The model with the smallest AIC has the higher predictive value. A probability value of 5% was considered statistically significant. All statistical calculations were performed using SPSS version 12.0 software (SPSS Inc, Chicago, IL, USA).
Results

Baseline Characteristics
Of the 2,172 patients enrolled in the study, 68% had normal or minimally impaired renal function, 27% had moderate renal dysfunction and 5% had severe renal dysfunction. Regarding diagnosis, among patients with UA, NSTEMI and STEMI, 5.73%, 6.13% and 4.28%, respectively, had severe renal impairment (p=0.008). Table 1 shows the baseline characteristics of patients hospitalized with all clinical presentations of ACS across the 3 categories of renal function. Patients with moderate and severe renal dysfunction at the time of admission were older and more likely to be women, to have a history of hypertension, diabetes mellitus or coronary heart disease compared with those with normal or minimally impaired renal function. Cigarette smoking was less frequent among patients with moderate or severe renal dysfunction, and body mass index was lower in those patients. A similar relationship between the degree of renal dysfunction and baseline characteristics was observed in both the STEMI and NSTEMI/UA subgroups of patients (Table 2 ). NSTEMI and UA was treated as 1 category because these 2 groups of patients were homogeneous with regard to risk factors, particularly creatinine clearance rate, which was the main factor studied by us. In particular, the mean ± standard deviation of creatinine clearance was 84.8±52.6 ml/min, 74.1±33.3 ml/min and 77.4±47.0 ml/min, respectively, for those with STEMI, NSTEMI and UA, (pvalue for difference in mean creatinine clearance between NSTEMI and UA after Bonferroni correction was 0.741).
Pre-Hospital Delay and In-Hospital Management
Among patients with STEMI, 63% of those with normal renal function or mild renal dysfunction, 43% of those with moderate renal dysfunction and 33% of those with severe renal dysfunction received thrombolytic therapy (p<0.001).
Regarding the time between onset of symptoms and admission to hospital, patients with severe renal dysfunction seemed to delay more than the other patients. The median (25 th , 75 th inter-quartiles) pre-hospital delay for all patients, for patients with STEMI and those with NSTEMI or UA are shown in Tables 1 and 2 . Among patients admitted with all clinical presentations of ACS, 39%, 35% and 28% of those with severe, moderate renal dysfunction and normal function, respectively, presented at hospital 6 h after the onset of symptoms (p=0.043), whereas among patients with STEMI or NSTEMI/UA 37% and 43%, respectively, of those with severe renal dysfuction delayed seeking medical care for more than 6 h from the onset of symptoms (p=0.761, p=0.049, respectively).
In-Hospital Cardiovascular Mortality
Overall, patients with renal dysfunction had a significantly higher crude in-hospital mortality rate than those with normal or minimally impaired renal function. There was a 
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progressive increase in the mortality rate with increasing severity of renal impairment (1.74% for normal renal function or mild renal insufficiency, 6.77% for moderate renal insufficiency and 15.84% for severe renal insufficiency, p<0.001) (Fig 1) . Because differences in the baseline characteristics and in-hospital management of patients may account for the aforementioned relationship, we performed multiple logistic regression analyses that evaluated the association between in-hospital mortality and renal insufficiency, after controlling for many potential confounders. After adjustment, patients with moderate and severe renal insufficiency seemed to have almost 3-and 12-fold higher odds of dying, respectively, compared with patients with normal or minimally impaired renal function (odds ratio (OR) 3.03; 95% confidence interval (CI) 1.02-9.47 for moderate renal dysfunction; OR 11.7; 95% CI 3.36-40.92 for severe renal dysfunction compared with normal renal function, Table 3 ). A similar relationship between renal insufficiency and in-hospital mortality was revealed in both STEMI and NSTEMI/UA subgroups (Table 3 , p-value for interaction 0.65). The AIC statistic was almost similar in both models (-30.21 for STEMI; -34.40 for NSTEMI/UA). Therefore, no was difference in the predictive value of the CrCl between the 2 subgroups. Using the CrCl as the continuous variable in the models, we observed that a 5 ml/min increment in CrCl leads to almost 15% decrease in the likelihood of death (OR 0.96; 95% CI 0.95-0.97). The same effect was observed in both STEMI and NSTEMI/UA subgroups and did not change even after controlling for several confounders.
Discussion
In the present study, we observed that renal dysfunction is associated with a poor prognosis in patients with ACS and that varying degrees of renal insufficiency are common among patients presenting with ACS. In particular, about 1 in 3 patients presented with moderate or severe renal dysfunction (32%), which is a similar frequency to that observed in recently published studies. 15, 17, 18 Regarding the baseline characteristics of patients with renal dysfunction and ACS, our results are in concordance with those of previous studies. 6, 8, [13] [14] [15] [16] [17] [18] [19] We observed that moderate and severe renal insufficiency were more frequent among older and female patients. It is well known that renal function decreases as age increases. Given that the women presenting at hospital with ACS were almost 5 years older than the men, that may explain the predominance of women among patients with impaired renal function. In addition, our findings demonstrate that renal insufficiency is an independent predictor for in-hospital mortality of patients presenting with a range of ACS. These results are in agreement with those of prior studies investigating the relationship of renal insufficiency and adverse outcomes among patients with coronary artery disease, beyond acute myocardial infarction (AMI). The investigators of the prospective multicenter SYCOMORE study, in which 496 patients with ACS were enrolled, found that decreasing renal function is an independent prognostic factor not only for in-hospital mortality but also for bleeding and contrastinduced nephropathy. 18 The largest, multinational observational study including patients with the complete spectrum of ACS concluded that the likelihood of dying during hospitalization after adjustment for potential confounders was almost 2-and 4-fold higher in patients with moderate or severe renal dysfunction, respectively, compared with those with normal or minimally impaired renal function. 15 Masoudi et al, in a study of 2,706 patients discharged from 24 Veterans Health Administration medical centers with a diagnosis of AMI or UA, demonstrated that moderate or severe renal insufficiency was independent predictor for 7-month mortality and that this association was similar in both AMI and UA subsets. 13 It has been suggested that 4 main factors may account for this poor prognosis of patients with renal insufficiency and ACS: (1) presence of important comorbidities such as diabetes mellitus, hypertension, elevated triglycerides, lower levels of high-density lipoprotein cholesterol and elevated lipoprotein(a) levels among patients with chronic kidney disease and end-stage renal disease; (2) underuse of cardioprotective therapies such as angioplasty, throm- bolytic agents and revascularization; (3) toxicity of therapy; and (4) abnormal vascular biology in chronic kidney disease including changes in coagulation, homocysteine, endothelial dysfunction and many other factors that have been related to cardiovascular disease. 25 Concerning the pre-hospital delay, we observed that patients with moderate or severe renal insufficiency delayed more than those with normal renal function in seeking medical care after the onset of symptoms of acute coronary disease. This could be attributed to the fact that diabetes mellitus is more common among patients with renal dysfunction and it is known that diabetics have impaired sensation of myocardial ischemic pain. 26 Finally, our results demonstrate that patients presenting with severe renal insufficiency and STEMI have a high risk of dying (37% in-hospital mortality rate), but despite their increased risk of adverse outcome the use of thrombolytic therapy was less frequent. This finding corroborates the results of other previous investigations [5] [6] [7] and may be explained, at least in part, by the increased age of patients with moderate or severe renal dysfunction, as well as their late arrival at hospital.
Study Limitations
Although this study is a large, national study, it has several limitations. First, CrCl was estimated from the Cr level and was not measured directly. The Cockroft's formula was used to estimate CrCl and it is not perfect. Moreover, we did not have information about the medications that the patients received during their hospitalization, so it is possible the results of this study are in part a reflection of this unmeasured confounder. However, given that our results corroborate the findings of other studies, which were controlled for treatment differences, this limitation cannot be considered as very strong. Additionally, this study did not address other outcome measures such as bleeding or stroke. Finally, information about the performance of coronary intervention was not recorded; because it was not able to be performed in 5 of the 6 hospitals participating in the study. This is an important limitation because it may be less likely for patients with renal insufficiency to receive coronary intervention and it is possible for it to affect the clinical outcome of patients.
Conclusions
The results of our study reveal that not only severe but also moderate renal insufficiency is an independent predictor of in-hospital mortality for patients hospitalized with a broad range of ACS and for those presenting separately with STEMI or NSTEMI/UA. Therefore, clinicians should take into account the presence or absence of renal dysfunction for risk stratification of patients admitted with ACS. Moreover, despite the increased risk of dying in patients with renal dysfunction, it was observed that they seek medical care later than other patients and that the treatment they receive is less aggressive. Future studies should be conducted in order to delineate the optimal management strategy for patients with renal insufficiency and ACS so as to improve the outcome of these patients.
